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Background: Cut-point finding is a crucial step for clinical decision making when dealing with diagnostic (or
prognostic) biomarkers. The extension of ROC-based cut-point finding methods to the case of censored failure time
outcome is of interest when we are in the presence of a biomarker, measured at baseline, used to identify whether
there will be the development, or not, of some disease condition within a given time point τ of clinical interest.
Methods: Three widely used cut-point finding methods, namely the Youden index, the concordance probability and
the point closest to-(0,1) corner in the ROC plane, are extended to the case of censored failure time outcome resorting
to non-parametric estimators of the sensitivity and specificity that account for censoring. The performance of these
methods in finding the optimal cut-point is compared under Normal and Gamma distributions of the biomarker (in
subjects developing or not the disease condition). Normality ensures that estimators point theoretically to the same
cut-point. Two motivating examples are provided in the paper.
Results: The point closest-to-(0,1) corner approach has the best performance from simulations in terms of mean square
error and relative bias.
Conclusions: We discuss the use of the Youden index or concordance probability associated to the cut-point identified
through the closest-to-(0,1) corner approach to ease interpretability of the classification performance of the dichotomized
biomarker. In addition, the achieved performance of the dichotomized biomarker classification associated to the estimated
cut-point can be represented through a confidence interval of the point on the ROC curve.
Keywords: Optimal cut-point, Censored failure time outcome, Youden index, Concordance probability, Point
closest-to-(0,1) corner in the ROC planeBackground
The use of a continuous biomarker X in clinical practice
often requires the definition of a cut-point c above (or
below) which subjects are classified, for instance, as
diseased and disease-free. In the presence of a binary
outcome, methods based on the receiver operating
characteristic (ROC) curve are commonly and indis-
tinctly used. These methods are based on objective
functions of c:
i) the Youden function, defined as the difference
between the probability of X > c in diseased subjects
(sensitivity, SE) and the complement to one of the
probability of X ≤ c in disease-free subjects* Correspondence: laura.antolini@unimib.it
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unless otherwise stated.(specificity, SP), i.e. SE + SP-1. The chosen c
maximizing this function, or equivalently SE + SP, leads
to a maximum value known as Youden index [1];
ii) the concordance probability function, equal to the
product of SE and SP, where the chosen c
maximizes this function [2,3];
iii) the distance between the point (1-SP, SE) and the
optimal point (0,1) in the ROC plane [4], where the
chosen c leads to the minimum distance, and the
operating point is referred as point closest-to-(0,1)
corner.
A recently published work compared these methods by
simulation in the case of a binary outcome [5]. The authors
showed that the point closest-to-(0,1) corner [4] and con-
cordance probability [2,3] methods outperformed both the
Youden index [1] and the minimum P-value approaches [6].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to the case of censored failure time outcome is of inter-
est when we are in the presence of a biomarker, mea-
sured at baseline in a cohort of disease-free subjects,
and used to understand whether there will be the devel-
opment, or not, of a disease condition within a given
time point τ of clinical interest. However, this extension
is not straightforward. In fact, both SE and SP cannot
be estimated by simple proportions as in the case of a
binary outcome, because it is not known whether cen-
sored subjects should be considered as diseased or
disease-free up to τ. As a consequence, a suitable esti-
mator for SE and SP need to be used to account for the
presence of censoring.
We aimed to extend the Youden index, concordance
probability and point closest-to-(0,1) corner cut-point
estimation methods to the case of censored failure time
outcome. The performance of the aforementioned methods
in finding the optimal cut-point is compared under Normal
homoscedastic and Gamma distributions of the biomarker
in diseased and disease-free subjects [7]. Normality ensures
that estimators point theoretically to the same cut-point, as
previously shown and described [2,5].
For each method, the optimal cut-point is empirically
estimated by maximization of objective functions [8]
using the estimators for SE and SP derived in Antolini
and Valsecchi [9]. To illustrate the methodology, two ap-
plication examples are provided, one in an observational
study of a molecular biomarker in acute lymphoblastic
leukemia [10], and one concerning the definition of a
prognostic score for patients with primary biliary cirrho-
sis enrolled in a randomized clinical trial [11].
Methods
Notations and basics
For a generic subject, let Z be the survival time, defined
as the time elapsed between some initial time point,
where the subject is disease-free, and the development
in time of disease. Let τ be a time horizon of clinical
interest. The definition of disease and disease-free condi-
tions depends on whether Z ≤ τ or Z > τ. It is assumed
that increasing values of the biomarker X are related to
a possible increment of the risk of becoming diseased.
Otherwise, without loss of generality, take the negative
of X. For any cut-point c that defines a binary classifica-
tion rule, a generic subject is said to be testing positive
or negative depending on whether X > c or X ≤ c.
In this context, SE and SP at c are defined as the prob-
ability of testing positive given that the subject is diseased
SE cð Þ ¼ P X > c Zi≤τj Þð ð1Þ
and as the probability of testing negative given that the
subject is disease-freeSP cð Þ ¼ P X≤c Zi > τj Þ:ð ð2Þ
The ROC curve is defined as the plot of SE(c) across
1-SP(c), for varying c. It is represented in Figure 1,
panel A.
The Youden function of c is the difference between
SE(c) and 1-SP(c):
J cð Þ ¼ SE cð Þ þ SP cð Þ−1: ð3Þ
J(c) takes values between 0, when SE(c) = 1-SP(c), and
1 when SE(c) = SP(c) = 1. The behavior of (3) is repre-
sented in Figure 1 panel B, thick line segment. The You-
den index J [1] is defined as the maximum of the
Youden function (3), or equivalently of SE(c) + SP(c).
Graphically, J represents the maximum vertical distance
between the ROC curve and the diagonal chance line
representing a useless biomarker. It can be also inter-
preted as the maximum net gain of the true positive
fraction (SE) with respect to the false positive fraction,
i.e. 1-SP (Figure 1 panel A thick line segment). The c
maximizing (3) is the optimal cut-point.
The concordance probability function [2,3] of c is the
product of SE(c) and SP(c):
CZ cð Þ ¼ SE cð Þ⋅SP cð Þ: ð4Þ
CZ(c) ranges between 0 if either SE(c) = 0 or SP(c) = 0,
and 1 in the ideal case where SE(c) = SP(c) = 1. CZ(c)
could be also expressed as the area of a rectangle on the
ROC curve of width SP(c) and height SE(c) and inter-
preted as probability of being below or beyond c for any
random pair of disease-free and diseased subjects (Figure 1
panel A, dotted line). The behaviour of (4) is represented
in Figure 1 panel B, dotted line. The optimal cut-point ac-
cording to this method is the c that maximizes (4).
The objective function defined as the distance between
the couple (1-SP(c), SE(c)) and the optimal point (0,1) –
representing maximum specificity (SP = 1) and maximum
sensitivity (SE = 1) - in the ROC plane (Figure 1 panel A, thin
line segment) is obtained by applying the Euclidean distance
ER cð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 − SE cð Þð Þ2 þ 1 − SP cð Þð Þ2
q
: ð5Þ
The behaviour of (5) is represented in Figure 1 panel
B, thin line segment. The optimal cut-point according to
this method is the c that mimimizes (5).
The three objective functions (3), (4) and (5) lead the-
oretically to the same cut-point copt when considering
homoscedastic Normal distributions of the biomarker in
diseased and disease-free subjects (Figure 1). A formal
proof is showed in Liu [2].
Optimal cut-point estimation
Let Ti = min(Zi,Ci) be the observed time, where Zi is
the time to event (development of disease) and Ci the
Figure 1 Cut-point finding methods background. Panel A. ROC-based objective functions. J(cJ) is the thick line segment. CZ(cCZ) is the area of
the dotted rectangle and ER(cER) is the thin line segment. Panel B. Behaviour of the population objective functions J(c) (thick line), CZ(c) (dotted
line) and ER(c) (thin line). CZ(c) is multiplied by 1.10. In the two panels, the biomarker X is generated according to N(2.56,1) or N(0,1), depending
on whether Z≤ τ or Z > τ, respectively, leading to J = 0.8, CZ = 0.81, ER = 0.14.
Rota et al. BMC Medical Research Methodology  (2015) 15:24 Page 3 of 11right censoring time, δi the censoring indicator (δi = 1
if Ti = Zi and δi = 0 if Ti = Ci) and Xi the biomarker
value for subject i. Independence completely at
random between Z and C is assumed as in the classical
framework of survival analysis. In our setting, the
biomarker X is measured at baseline in order to
identify ahead in time subjects that will develop disease
or not within τ. The observed data in a sample of size
N is {(Xi, Ti, δi); i = 1, …, N}, and it can be subdivided
in three subgroups:
i) Disease-free, if Ti > τ regardless of δi;
ii) Diseased, if Ti ≤ τ and δi = 1;
iii)Censored by τ while Disease-free, if Ti ≤ τ and δi = 0;
with cardinality nz>τ ¼
XN
i¼1I Ti > τð Þ; nz≤τ ¼
XN
i¼1 I
Ti≤τð Þ δi and nC ¼
XN
i¼1I Ti ≤ τð Þ 1 − δið Þ, respectively.
For the nc subjects belonging to iii), the disease status
by τ is unknown as it is not possible to know whether
they would experience or not the disease within τ if
censoring would not have occurred. This leads for any c




i ¼ 1I Xi≤cð Þ and nX>c ¼
XN
i ¼1I
Xi > cð Þ.In this setting, SE(c) (1) and SP(c) (2) are not directly
estimable from (6) since it is not known how the nc
subjects would contribute to the classification 2x2
matrix contrasting the disease status for all N subjects to
the biomarker classification.
Nonparametric estimators of SE(c) (1) and SP(c) (2) can
be derived following two different approaches, the direct or
the indirect one, that were recently discussed and shown to
be equivalent by Antolini and Valsecchi [9]. Direct estima-
tion is based on an inverse probability weighting scheme
applied to the counts of the groups of disease-free and
diseased subjects in the classification matrix (6) (lines 1 and
2), and originates from the consideration that subjects with
observed status are selected from the censoring process
and can be weighted to represent the subjects that are
censored (line 3 of matrix (6)). Indirect estimation relies on
writing SE and SP in terms of quantities that are estimable
from the available data in the presence of censoring, and on
plugging-in the estimates.
A further approach, equivalent to the aforementioned
ones, consists in estimating the expected number of
events in each of the four cells of the 2×2 classification
matrix contrasting the disease status for all N subjects to
the biomarker classification, as follows:
The two survival estimates S^X>c τð Þ ¼ P^ Z > τ X > cj Þð
and S^X≤c τð Þ ¼ P^ Z > τ X≤cj Þð are simply obtained by the
Kaplan-Meier method in the two samples as classified ac-
cording to the biomarker value X.
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from matrix (7) by simple proportions as










S^P cð Þ ¼ S^X≤c τð Þ⋅nX≤c
S^X≤c τð Þ⋅nX≤c þ S^X>c τð Þ⋅nX>c
: ð9Þ
As an alternative, one could use the indirect estima-
tors of SE(c) and SP(c) based on nearest neighbor
estimates of the joint survival between X and Z [12].
This could have the advantage to relax the assumption
of independence completely at random between C and
Z since it requires only conditional independence
given X.
The investigated ROC-based cut-point finding methods
could be now easily extended to the censored failure time
outcome scenario by plugging-in sample estimates (8) and
(9) into objective functions (3), (4) and (5). The optimal
cut-point estimates ĉJ, ĉCZ and ĉER are then obtained by
maximizing the objective functions (3), (4) and (5) over all
possible cut-point values c of X [8].
It is worth of note that although the three methods
point theoretically to the same cut-point under Nor-
mal homoscedastic distributions of the biomarker in
diseased and disease-free subjects, the corresponding
sample estimators here presented do not lead necessarily
to the same estimated cut-point in a single sample. This
motivates the estimator performance comparison pre-
sented in the next section.
Simulation protocol
We conducted a simulation study to compare the per-
formance of the Youden index (3), the concordance
probability (4) and the point closest-to-(0,1) corner in
the ROC plane (5) methods in the estimation of the op-
timal cut-point in a censored failure time outcome
scenario.
Data were simulated as follows:
 The time-to-event Z was generated according to an
exponential survival function S(t) = 1 − e− 2t.
 τ was set equal to 0.35 in order to achieve a disease
fraction of 50% and to 0.20, 0.14, 0.11 and 0.08 to
achieve disease fractions of 33%, 25%, 20% and 15%.
 Depending on whether Z ≤ τ or Z > τ, the biomarker
X was generated according to N(μZ≤τ, 1) or N(0,1),
respectively. This leads to SE(c) = 1 −Φ(c − μZ ≤ τ) and
SP(c) =Φ (c), where Φ denotes the standard Normal
distribution function. It has been previously shown
that within this scenario the objective functions (3),(4) and (5) reach their maximum in correspondence
of the same true cut-point, i.e. copt = μZ ≤ τ/2 [2,5].
Analytically, this common cut-point occurs at the
intersection between the Normal probability density
functions of diseased, i.e. fZ>τ (c), and disease-free
subjects, i.e. fZ>τ (c).
 Similarly, X was generated according to G(2.5, βZ≤τ)
and G(1.5,1) depending on whether Z ≤ τ or Z > τ.
This implies that SE cð Þ ¼ 1








scenario, the objective functions (3), (4) and (5) point
to different true cut-points, and a closed form for copt
cannot be derived [2,5].
 μZ≤τ was set equal to {0.51, 1.05, 1.68, 2.56} and βZ≤τ
to {0.79, 1.22, 1.97, 3.82} in order to achieve a wide
variety of the classification accuracy, i.e. J(cJ) = {0.2,
0.4, 0.6, 0.8}, CZ(cCZ) = {0.36, 0.49, 0.64, 0.81},
ER(cER) = {0.57, 0.42, 0.28, 0.14}, ranging from a
poor one (J = 0.2, CZ = 0.36 and ER = 0.57) to a high
one (J = 0.8, CZ = 0.81 and ER = 0.14).
 The simulation of the survival times first, and
thereafter the biomarker values, is somehow
counterintuitive since the “natural” ordering
suggests that time should be generated depending
on the biomarker values, and not vice versa. This
choice was done only to keep directly under control
the theoretical values of SE and SP, and thus of the three
objective functions, Youden index (3), concordance
probability (4) and point closest-to-(0,1) corner (5).
 To simulate independent censoring, the censoring time
C was generated according to a uniform distribution in
the interval [0,b]. When we considered the scenario
with a disease fraction equal to 50%, b was set equal to
2, 1 and 0.66 time units in order to achieve different
censoring levels, i.e. 12%, 25% and 38%. Within the
scenarios with disease fraction equal to 33%, 25%, 20%
and 15%, b was set equal to 0.67, 0.50, 0.40 and 0.29
time units to achieve a censoring level of 25%.
 The observed survival data was calculated by
T =min(Z,C) and δ = 1 if T = Z and δ = 0 if T = C.
We generated 1000 samples {(Xi, Ti, δi); i = 1, …, N} of
size N = 50, N = 100, N = 200 and N= 400 with a disease
fraction of 50% and three different censoring levels, i.e.
12%, 25% and 38%. Moreover, we generated 1000 samples
of size N = 100, N = 150, N = 200 and N= 250 with differ-
ent disease fractions, i.e. 33%, 25%, 20% and 15%, and a
censoring level of 25%. For each sample, we determined by
empirical numerical maximization [2,5,8] the optimal
cut-point estimates ĉJ, ĉCZ and ĉER for the Youden index,
the concordance probability and the point closest-to-(0,1)
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tive bias and the mean square error (MSE) of each method
were computed by E[(ĉ. − c)] and E[(ĉ. − c)
2], where the ex-
pectation was meant to be the average over the N simu-
lated samples.
Given the computational burden, we applied the boot-
strap resampling technique to estimate the standard de-
viation and the confidence interval (CI) for the optimal
cut-point for some selected scenarios with sample size
N = 100 or N = 150. We applied the Efron and Tibshirani’s
procedure [13] as follow:
 From each sample {(Xi, Ti, δi); i = 1, …, N}, we
applied a random sampling with replacement to
draw 200 bootstrap samples in order to calculate the
bootstrap estimate ĉB (B = 1, …, 200).
 We applied the basic percentile method, taking the
0.025 and 0.975 percentiles of the ĉB bootstrap
distribution in order to construct a 95% CI of the
optimal cut-point within each of the 1000 generated
samples. Each bootstrap sample contributed one
cut-point estimate, so that the standard deviation of
the 200 cut-point estimates was used as the boot-
strap estimator of the standard deviation (SDB) for
the estimated cut-point.
 The CI for the cut-point for each of the investigated
methods was subsequently evaluated by computing
coverage probability and mean length.Table 1 Relative bias and Mean Square Error (MSE) of the cut-p




‡ copt N Relative bias MSE
















†XZ ≤ τ ~ N(μZ ≤ τ, 1), XZ >τ ~ N(0, 1).
‡The levels of J and CZ are achieved by μZ ≤ τ = 0.5Simulations have been performed in R version 2.15 [14].
Results
Simulation study
The results of the simulation exercises under Normal
homoscedastic distribution of X with a diseased and
disease-free fraction of 50% are shown in Tables 1, 2 and 3
for different censoring levels, i.e. 12%, 25% and 38%, re-
spectively. The relative bias of the investigated methods is
small on all levels of classification accuracy, except for the
scenario with J = 0.2 and CZ = 0.36 for samples of size
N = 50 and N = 100, and it increases as the censoring
level increases. By comparing the MSEs, it can be no-
ticed that the point closest-to-(0,1) corner in the ROC
plane and the concordance probability methods have
better performance than the Youden index method. In-
deed, the MSE is inversely related to sample size and it
increases as the censoring level increases. The perform-
ance of the investigated methods improves with increasing
classification accuracy.
Table 4 shows the results under Normal homoscedastic
distribution of X when considering different disease frac-
tions and a censoring level of 25%. The relative bias of the
investigated methods is small on all levels of classification
accuracy, except for the scenarios with a disease fraction
equal to 15%. As above, the point closest-to-(0,1) corner in
the ROC plane and the concordance probability methods
outperform the Youden index method. The MSE is loweroint in the normal homoscedastic scenario† with diseased
Concordance probability Point closest-to-(0,1) corner
Relative bias MSE Relative bias MSE
0.1503 0.1264 0.1854 0.0891
0.0687 0.0719 0.0769 0.0513
0.0546 0.0501 0.0589 0.0360
0.0507 0.0273 0.0404 0.0199
0.0623 0.1158 0.0618 0.0785
0.0346 0.0724 0.0356 0.0462
0.0009 0.0462 0.0032 0.0279
0.0070 0.0270 0.0100 0.0147
0.0599 0.1157 0.0555 0.0763
0.0350 0.0675 0.0259 0.0421
0.0201 0.0408 0.0152 0.0227
0.0015 0.0240 −0.0009 0.0138
0.0531 0.1117 0.0528 0.0880
0.0379 0.0669 0.0291 0.0465
0.0149 0.0383 0.0115 0.0241
0.0021 0.0253 0.0027 0.0148
1, 1.05, 1.68, 2.56, respectively.
Table 2 Relative bias and Mean Square Error (MSE) of the cut-point in the normal homoscedastic scenario† with
diseased and disease-free fractions of 50% and a censoring level of 25%
Youden index Concordance probability Point closest-to-(0,1) corner
J(copt)
‡ CZ(copt)
‡ copt N Relative bias MSE Relative bias MSE Relative bias MSE
0.2 0.36 0.25 50 0.1327 0.3204 0.1582 0.1366 0.1498 0.0983
100 0.1172 0.2448 0.1078 0.0798 0.1016 0.0565
200 0.0777 0.1951 0.0796 0.0525 0.0561 0.0388
400 0.1123 0.1196 0.0541 0.0304 0.0408 0.0214
0.4 0.49 0.52 50 0.0728 0.2029 0.0740 0.1202 0.0739 0.0793
100 0.0490 0.1332 0.0327 0.0771 0.0339 0.0489
200 0.0200 0.0946 0.0101 0.0522 0.0031 0.0294
400 0.0042 0.0573 0.0037 0.0274 0.0075 0.0157
0.6 0.64 0.84 50 0.0651 0.1446 0.0589 0.1182 0.0477 0.0817
100 0.0491 0.0947 0.0428 0.0428 0.0355 0.0355
200 0.0185 0.0605 0.0237 0.0447 0.0192 0.0237
400 0.0058 0.0367 0.0055 0.0255 0.0004 0.0148
0.8 0.81 1.28 50 0.0514 0.1236 0.0523 0.1158 0.0473 0.0990
100 0.0384 0.0786 0.0373 0.0722 0.0299 0.0505
200 0.0149 0.0464 0.0140 0.0401 0.0081 0.0259
400 0.0053 0.0314 0.0064 0.0271 0.0024 0.0158
†XZ ≤ τ ~ N(μZ ≤ τ, 1), XZ >τ ~ N(0, 1).
‡The levels of J and CZ are achieved by μZ ≤ τ = 0.51, 1.05, 1.68, 2.56, respectively.
Table 3 Relative bias and Mean Square Error (MSE) of the cut-point in the normal homoscedastic scenario† with diseased
and disease-free fractions of 50% and a censoring level of 38%
Youden index Concordance probability Point closest-to-(0,1) corner
J(copt)
‡ CZ(copt)
‡ copt N Relative bias MSE Relative bias MSE Relative bias MSE
0.2 0.36 0.25 50 0.1345 0.3419 0.1918 0.1514 0.1812 0.1099
100 0.1347 0.2592 0.1042 0.0894 0.1225 0.0627
200 0.0547 0.2084 0.0638 0.0572 0.0652 0.0413
400 0.0932 0.1395 0.0177 0.0350 0.0200 0.0245
0.4 0.49 0.52 50 0.0912 0.2147 0.0829 0.1303 0.0624 0.0891
100 0.0595 0.1418 0.0460 0.0841 0.0438 0.0518
200 0.0106 0.1039 0.0082 0.0541 0.0024 0.0339
400 0.0085 0.0641 −0.0021 0.0314 0.0009 0.0173
0.6 0.64 0.84 50 0.0446 0.1596 0.0560 0.1262 0.0507 0.0890
100 0.0628 0.1094 0.0599 0.0794 0.0492 0.0494
200 0.0258 0.0653 0.0256 0.0492 0.0212 0.0260
400 0.0042 0.0408 0.0052 0.0287 0.0012 0.0160
0.8 0.81 1.28 50 0.0461 0.1404 0.0435 0.1340 0.0310 0.1186
100 0.0449 0.0883 0.0411 0.0792 0.0282 0.0587
200 0.0132 0.0503 0.0108 0.0462 0.0073 0.0297
400 0.0039 0.0367 0.0041 0.0323 0.0030 0.0185
†XZ ≤ τ ~ N(μZ ≤ τ, 1), XZ >τ ~ N(0, 1).
‡The levels of J and CZ are achieved by μZ ≤ τ = 0.51, 1.05, 1.68, 2.56, respectively.
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Table 4 Relative bias and Mean Square Error (MSE) of the cut-point in the normal homoscedastic scenario† with different
disease fractions and a censoring level of 25%
Youden index Concordance probability Point closest-to-(0,1) corner
J(copt)
‡ CZ(copt)
‡ copt N Disease fraction Relative bias MSE Relative bias MSE Relative bias MSE
0.2 0.36 0.25 100 15% 0.2296 0.3298 0.4150 0.1390 0.4114 0.1060
150 33% 0.2188 0.2089 0.1921 0.0611 0.1749 0.0440
200 25% 0.0973 0.2125 0.1758 0.0666 0.1822 0.0482
250 20% 0.1872 0.1871 0.2246 0.0592 0.2164 0.0421
0.4 0.49 0.52 100 15% 0.1389 0.1944 0.2084 0.1320 0.2450 0.1051
150 33% 0.0786 0.1048 0.0625 0.0575 0.0741 0.0370
200 25% 0.0516 0.1147 0.0701 0.0606 0.0674 0.0381
250 20% 0.0926 0.0990 0.0951 0.0528 0.0940 0.0346
0.6 0.64 0.84 100 15% 0.1457 0.1658 0.1503 0.1366 0.1765 0.1101
150 33% 0.0522 0.0778 0.0547 0.0590 0.0453 0.0367
200 25% 0.0500 0.0744 0.0516 0.0512 0.0515 0.0286
250 20% 0.0543 0.0742 0.0585 0.0569 0.0596 0.0344
0.8 0.81 1.28 100 15% 0.1219 0.1534 0.1283 0.1478 0.1337 0.1274
150 33% 0.0401 0.0702 0.0439 0.0645 0.0387 0.0432
200 25% 0.0360 0.0568 0.0375 0.0513 0.0438 0.0364
250 20% 0.0535 0.0641 0.0558 0.0585 0.0535 0.0390
†XZ ≤ τ ~ N(μZ ≤ τ, 1), XZ >τ ~ N(0, 1).
‡The levels of J and CZ are achieved by μZ ≤ τ = 0.51, 1.05, 1.68, 2.56, respectively.
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method, too.
The results of the simulation exercise under Gamma dis-
tribution of X when considering a diseased and disease-free
fraction of 50% and a censoring level of 25% are shown inTable 5 Relative Bias and Mean Square Error (MSE) of the cut




‡ cJ cCZ cER N Relative bias M
















†XZ ≤ τ ~ G(2.5, βZ ≤ τ), XZ >τ ~ G(1.5, 1).
‡The levels of J and CZ are achieved by βZ ≤ τ =Table 5. In such scenario, the three objective functions
point to different cut-points, and only a relative perform-
ance comparison could be made. We note that methods’
performance improve with increasing classification accur-
acy in terms of relative bias, and also that the Youden index-point in the Gamma scenario† with diseased and disease-
Concordance probability Point closest-to-(0,1) corner
SE Relative bias MSE Relative bias MSE
822 0.0532 0.1584 0.0464 0.1235
987 0.0429 0.0975 0.0352 0.0712
825 0.0138 0.0638 0.0087 0.0446
156 0.0105 0.0348 0.0086 0.0261
446 0.0605 0.2700 0.0473 0.1771
585 0.0408 0.1529 0.0311 0.1001
740 0.0136 0.0924 0.0059 0.0521
183 0.0133 0.0571 0.0062 0.0346
201 0.0411 0.4108 0.0383 0.2741
288 0.0293 0.2380 0.0267 0.1536
117 0.0170 0.1539 0.0138 0.0815
433 0.0077 0.0941 0.0081 0.0445
808 0.0663 0.9103 0.0782 0.7477
678 0.0508 0.5156 0.0429 0.3593
317 0.0241 0.3039 0.0166 0.1739
929 0.0107 0.1693 0.0079 0.0885
0.79, 1.22, 1.97, 3.82, respectively.
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nario with J = 0.2 and CZ = 0.36 for samples of size N = 50
and N= 100. The MSE is inversely related to sample size
but it increases as the classification accuracy increases. As
in the Normal scenarios, the MSE is lower for the point
closest-to-(0,1) corner in the ROC plane method.
Bootstrap standard deviation, coverage probability and
mean length of the 95% bootstrap CI for the cut-point
are shown in Additional file 1: Table S1 for some selected
simulation scenarios under Normal homoscedastic distribu-
tion of X. The SDB of the point closest-to-(0,1) corner in
the ROC plane approach is lower than the SDB of the You-
den index and concordance probability methods. Coverage
probabilities are fluctuating around the nominal level. 95%
bootstrap CIs were narrower when considering the scenar-
ios with better classification accuracies, i.e. J of 0.6 and 0.8.Applicative example on acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most com-
mon malignancy in children and it presents, in the large
majority (70%), a B-cell precursor (BCP) ALL immuno-
phenotype. The cure rate of BCP-ALL is nowadays
higher than 80%, but the probability of survival of pa-
tients who relapse is only 40% [10]. Recent studies had
reported that a higher expression of the cytokine
receptor-like factor 2 (CRLF2) was associated to a higher
risk of relapse. In their study, Palmi et al. [10] aimed at
defining a cut-point for the CRLF2, as measured at diag-
nosis, that would allow to identify those children more
likely to relapse in order to be able to tailor upfront the
treatment intensity in future protocols. We applied the
presented methods to this study that includes 464 Italian
BCP-ALL children enrolled (from February 2003 to July
2005) in the AIEOP (Associazione Italiana Ematologia
Oncologia Pediatrica) treatment protocol “AIEOP-BFMFigure 2 Applicative example on acute lymphoblastic leukemia. Panel A
Histogram for the CRLF2 expression. Panel C. ROC curve for the CRLF2 b
represented by the thick line segment, the concordance probability CZ
distance from the (0,1) corner represented by the thin line segment. Th
also represented.ALL2000”. The time window of interest for predicting
relapse was of 5 years, and in that time frame 74 relapses
had been observed over a total of 79 relapses in the co-
hort. Figure 2 Panel A shows the event free survival
(EFS) curve along with the 95% confidence bands. The
5-year EFS estimate was 81.6% (95% CI, 78.1%-85.1%).
The CRLF2 expression had a right-skewed distribution
(Shapiro-Wilk normality test P < 0.01) ranging from
0.006 to 810-fold change compared to the overall me-
dian value (Figure 2 Panel B) [10].
The estimated cut-point for the CRLF2 expression was
ĉ = 1.46, the same for all three methods, but the classifi-
cation accuracy of this biomarker was very low, as
depicted by the ROC curve and expressed by the Youden
index J = 0.10 calculated for the identified cut-point (Fig-
ure 2 Panel C). The 95% bootstrap (999 replicates) CI
estimates for the cut-point are (0.12, 21.61), (0.70, 1.98)
and (0.70, 1.86), for the Youden index, the concordance
probability and the point closest-to-(0,1) corner in the
ROC plane methods, respectively. The 95% delta-
method based elliptic asymptotic confidence interval of
(FPF(ĉ), TPF(ĉ)) is represented in Figure 2 Panel C. This
interval is elliptic in the logit space since it was obtained
from a joint interval on the logit transformation of ^TPF
and ^FPF; which are correlated, altough modestly, since
censored observations contribute to both estimators [9].Applicative example on primary biliary cirrhosis
We used data, made available online inside the survi-
valROC R package [15], from a randomized placebo-
controlled trial of D-penicilliamine (DPCA) for the
treatment of primary biliary cirrhosis (PBC), conducted
at the Mayo Clinic between 1974 and 1984. Among the
312 subjects randomized to the study, 125 died by the
end of the follow-up. The survival curve is shown in. Estimated survival curve with 95% confidence bands. Panel B.
iomarker with the three objective functions: the Youden index J(ĉJ)
(ĉCZ) represented by the area of the dotted rectangle and the
e 95% elliptic asymptotic confidence interval of (FPF(ĉ), TPF(ĉ)) is
Figure 3 Applicative example on primary biliary cirrhosis. Panel A. Estimated survival curve with 95% confidence bands. Panel B. Histogram for
the MAYOSCORE5 prognostic score. Panel C. ROC curve for the MAYOSCORE5 prognostic score with the three objective functions: the Youden
index J(ĉJ) represented by the thick line segment, the concordance probability CZ(ĉCZ) represented by the area of the dotted rectangle and the
distance from the (0,1) corner ER(ĉER) represented by the thin line segment. The 95% elliptic asymptotic confidence interval of (FPF(ĉ), TPF(ĉ)) is
also represented.
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used to develop a clinical prediction model for mortal-
ity based on bilirubin and albumin levels, prothrombin
time, presence of edema and age at diagnosis [11]. We
aimed to find a cut-point for this widely used prognostic
score (hereafter named MAYOSCORE5) by considering
a time frame of one year, i.e. τ = 365 days, from study
entry, by when 22 deaths occurred. The MAYOSCORE5
score ranged between 3.74 and 11.250 with a median of
5.75, and its distribution is quite symmetric (Figure 3
Panel B), even if not Normal according to a formal test
(Shapiro-Wilk normality test P < 0.01). The three inves-
tigated methods, i.e. the Youden index, the concordance
probability and the point closest-to-(0,1) corner in the ROC
plane, lead to the same estimated cut-point ĉ = 7.35. The
biomarker had a good classification accuracy, with a You-
den index J = 0.78 and a concordance probability CZ = 0.79,
as shown in Figure 3. The bootstrap (999 replicates) stand-
ard deviations for ĉ are 0.11, 0.09 and 0.05 for the Youden
index, concordance probability and point closest-to-(0,1)
corner in the ROC plane methods, respectively. Moreover,
the 95% bootstrap CI estimates for the cut-point are (6.99,
7.35), (7.03, 7.35) and (7.30, 7.48), for the Youden index, the
concordance probability and the point closest-to-(0,1) cor-
ner in the ROC plane methods, respectively. The 95%
delta-method based elliptic asymptotic confidence interval
of (FPF(ĉ),TPF(ĉ)) is represented in Figure 3 Panel C. This
interval is elliptic in the logit space since it was obtained
from a joint interval on the logit transformation of ^TPF
and ^FPF; which are correlated, altough modestly, since
censored observations contribute to both estimators [9].Discussion
In this work we extended three widely used ROC-based
methods for defining a cut-point of a continuousbiomarker, namely the Youden index [1], the concord-
ance probability [2,3] and the point closest to-(0,1) cor-
ner [4], to the censored failure time outcome by using
non-parametric estimators of sensitivity and specificity
in the presence of censoring [9]. The minimum p-value
approach [6] was not extended to the censored data set-
ting since its objective function is computed under the
null hypothesis of absence of association between the
true binary status and the biomarker classification, in
contrast with the presence of some discrimination po-
tential that leads to the dichotomization issue itself. In
fact, this last method showed an unsatisfactory perform-
ance when oriented to identify a cut-point in the pres-
ence of a binary outcome [5]. The same consideration
would also apply to other test-based methods such as
the log-rank, which in addition it is not specifically re-
lated to a predefined time horizon [16].
The simulation protocol was set in order to keep dir-
ectly under control the theoretical values of sensitivity
and specificity by simulating the survival times first, and
afterwards the biomarker values conditional on time.
This strategy can be however reversed by working with
the Bayes’ theorem.
We mainly considered the case where the three
methods identify theoretically the same underlying true
cut-point, as in the presence of Gaussian homoscedastic
biomarker distributions. The main issue a researcher
faces in this common situation is the choice between
alternative estimators of the same parameter (cut-point).
We showed that the point closest-to-(0,1) corner ap-
proach has the best performance from simulations in
terms of mean square error and relative bias. However,
the calculation of the Youden index [1] or the concord-
ance probability [2,3] associated to the cut-point identi-
fied through the point closest-to-(0,1) corner estimator
could be used to ease interpretability and to communicate
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lack of clinical meaning of the point closest-to-(0,1) corner
objective function [4].
In the absence of a closed form, we provided estima-
tion of the standard deviation and 95% confidence inter-
val for the cut-point by the bootstrap method [13]. We
used only 200 replicates due to computational burden of
the simulation exercise. This may have led to coverage
under the nominal level in some scenarios. We recom-
mend to use a larger number of replicates in real data
applications. In the applications presented in this paper,
we used 999 bootstrap replicates. In addition, the
achieved performance of the dichotomized biomarker
classification associated to the estimated cut-point can
be represented through a confidence interval of the
point on the ROC curve [9,17].
It should also pointed out that a good estimation of
the cut-point did not necessary lead to a good estima-
tion of the corresponding objective functions, and vice
versa [8]. In our simulation scenario, we found an over-
estimation of the Youden index and concordance prob-
ability, and an underestimation of the closest-to-(0,1)
corner objective function, at the optimal estimated cut-
point. The bias decreased with increasing sample size
and classification accuracy of the biomarker. This is due
to the fact that most properties of estimators, such as
bias, are not preserved under non-linear monotonic
transformations [8]. Thus, when communicating the
clinical value of an identified cut-point, we also recom-
mend to provide the confidence interval estimate of the
associated objective function. For the Youden index
method, the variability of the objective function estimate
in the presence of censored data can be addressed by ap-
plying the delta method and by handling the covariance
issue as in Antolini and Valsecchi [9].
When methods point to different true cut-points, as in
the Gamma distribution scenario, since the parameters
of interest are different, estimators cannot be solely
chosen relying on performance. In this case, scientists
should rather choose according to the meaning of the
underlying objective functions. For instance, the Youden
index method [1] could be chosen if the researcher is in-
terested in interpreting the net gain of the true positive
fraction accounting for the false positive fraction, while
the concordance probability approach [2,3] could be
used if the researcher aims to interpret the probability of
being below or above the cut-point for any random pair
of disease-free and diseased subjects. When the focus is
not on a specific time horizon, other cut-point finding
methods could be considered, such as Harrell’s C, or
even model-based derived indicators [16].
When disease prevalence is far from 50%, as in many
applications, the three investigated methods could be
modified by a weighting system in order to take intoaccount the relative importance attributed to a true posi-
tive or a true negative result by addressing aspects re-
lated to both disease prevalence and patient’s benefit
associated with a correct positive test result [18,19].
Moreover, in a setting with a high or poor overall survival,
the estimated cut-point may have larger variation [3]. It
has also to be considered that besides the relatively high/
poor overall survival, the investigated objective functions
do not generally lead to optimal cut-points on the bound-
ary of the biomarker distribution [5]. This is nice, since a
cut-point on the boundary could indeed lead to a very lim-
ited sample size for the estimation of one of the two con-
ditional survivals which are plugged into sensitivity and
specificity.
The proposed example on CRLF2 expression in acute
lymphoblastic leukemia [10] shows that in some clinical
applications methods based on sensitivity and specificity
may lead to unsatisfactory cut-points due to a moderate
discrimination potential of the biomarker, as represented
by the whole ROC curve. By contrast, the application
example on the Mayo score predicting mortality in pri-
mary biliary cirrhosis shows a satisfactory result.
Future works should address the issue of when cut-
point finding should be based on predictive values [20],
more appealing for clinical interpretation and use, rather
than on sensitivity and specificity. If the point of a bio-
marker based test is to use it to discriminate prognosis,
clinicians need to know the probability that the outcome
will be favourable or unfavourable given the test out-
come. In this way, clinicians would approach the data
from the direction of the test results, using predictive
values [21], although their cut-point definition would be
influenced by the prevalence of the condition. For ex-
ample, when predictive values had been used to detect a
cut-point for the CRLF2, as done in the original paper
[10], a very extreme value of the cut-point would have
been identified, which defines a very rare subgroup with
a high risk of relapse.Conclusions
We showed the extension of the Youden index, the con-
cordance probability and the point closest to-(0,1) cor-
ner in the ROC plane cut-point finding methods to the
case of censored failure time outcome. When consider-
ing the Normal homoscedastic scenario where the inves-
tigated methods lead to the same cut-point, the point
closest-to-(0,1) corner approach has the best perform-
ance from simulations in terms of mean square error
and relative bias. However, we discuss the use of the
Youden index or the concordance probability associated
to the cut-point identified through the closest-to-(0,1)
corner approach to ease interpretability of the classifica-
tion performance of the biomarker.
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